Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.
about
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma.Marital status independently predicts prostate cancer survival in men who underwent radical prostatectomy: An analysis of 95,846 individuals.
P2860
Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Impact of comorbidity on the o ...... cancer treated with docetaxel.
@ast
Impact of comorbidity on the o ...... cancer treated with docetaxel.
@en
type
label
Impact of comorbidity on the o ...... cancer treated with docetaxel.
@ast
Impact of comorbidity on the o ...... cancer treated with docetaxel.
@en
prefLabel
Impact of comorbidity on the o ...... cancer treated with docetaxel.
@ast
Impact of comorbidity on the o ...... cancer treated with docetaxel.
@en
P2860
P356
P1476
Impact of comorbidity on the o ...... cancer treated with docetaxel
@en
P2093
Andrej Zist
Bostjan Seruga
P2860
P304
P356
10.1515/RAON-2015-0038
P577
2015-11-27T00:00:00Z